WO2013120481A2

WO2013120481A2 - Use of an agent for stimulating the gene expression of antimicrobial peptides (amp)

Info

Publication number: WO2013120481A2
Application number: PCT/DE2013/100038
Authority: WO
Inventors: Adolf Klenk; Christoph Abels; Michael Soerberdt; Tobias Fischer
Original assignee: Dr. Kurt Wolff Gmbh & Co. Kg
Priority date: 2012-02-13
Filing date: 2013-02-05
Publication date: 2013-08-22
Also published as: DE102012002592A1; WO2013120481A3

Abstract

The object of the invention is to provide an agent which has good acceptability and stability and also gives rise to an antimicrobial effect. This object is achieved according to the invention in that the agent contains a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthine, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.

Description

DESCRIPTION

Use of an agent for stimulating gene expression of antimicrobial peptides

(AMP)

The present invention relates to the use of an agent for stimulating the gene expression of antimicrobial peptides (AMP).

Antimicrobial preparations have long been known in pharmacy and cosmetics. They serve to eliminate a microbiological imbalance on body surfaces or in the oral cavity. Interfaces of the human organism (body) to the environment, in particular the skin with its appendages, such as the sweat or sebaceous glands, the gastrointestinal, the respiratory tract and the vaginal area are covered with numerous microorganisms, without disturbing the physiological balance. Rather, certain bacterial species are even necessary for health maintenance. Thus acidifying bacteria, e.g. Lactobacilli, by production of lactic acid lower the pH in the vagina and thus reduce the colonization with pathogenic germs.

On certain body surfaces, skin lipids and other substances can be split and metabolized by microorganisms and the enzymes present there. The result is local skin irritation (due to the release of fatty acids) or unpleasant body odors. The formation of seborrheic scales is also the result of microbiological metabolites. This is followed by local irritation of the scalp or facial skin followed by hyperproliferation of the keratinocytes in the epidermis.

So far, it has been customary to use synthetic or natural biocidal substances against such microorganisms by external application. These biocides intervene in the cell metabolism of bacteria and prevent their colonization or reduce microbiological contamination. Such biocides are usually exogenous substances which have a certain toxicological potential, in particular biocides Sensitizing properties are known, which have led even in younger representatives of this group of substances to a ban or a use restriction in cosmetic products. Lipophilic alcohols are suitable as biocides, wherein, for example, DE 10 2010 027 947 A1 describes cyclohexanol as active ingredient in antiperspirants and deodorants. Caprylyl glycol in admixture with other biocides have been disclosed as a preservative system in DE 601 19 669 T2. Also elemental silver or silver ions have already been described as an active ingredient against microbiological body odor in cosmetic products. One of these disclosures is called, for example, DE 10 2009 027 604 AI.

However, a disadvantage of the latter two substances is that they are foreign to the body and therefore may also present risks in use.

Probiotic active principles have also been proposed as antimicrobial protection, for example in skin treatment compositions, as disclosed in DE 10 2004 032 734 A1, or for the treatment of the gastrointestinal tract (disclosed in EP 2 277 524 A1 or GB 2 382 528 A).

A completely different approach was presented in DE 10 2005 014 687 AI. There is described an addition of β-defensin, an antimicrobial peptide (AMP), in cosmetic products.

An antimicrobial peptide is a high-molecular-weight protein that only gets its effect through a certain steric spatial organization. It may therefore be doubted that it is possible to obtain particularly complex protein structures over the entire production route from the production or recovery of the protein to the finished cosmetic or pharmaceutical agent and to keep them stable over the entire storage life of the product.

Thus, there is so far no satisfactory solution of a biocidal active principle in pharmaceutical and cosmetic products, which meets both the requirements for the effect and the compatibility. The invention is therefore based on the object to provide an agent which has good compatibility and stability and stimulates the body's synthesis of antimicrobial peptides.

This object is achieved according to the invention in that the agent contains a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.

It is further envisaged that the use of the antimicrobial peptide stimulating agent (AMP) will in particular enhance the synthesis of the antimicrobial peptide dermcidin.

Dermcidin is a so-called antimicrobial peptide, which is synthesized in large quantities in the sweat glands and has only been detected there exclusively. It protects the epithelia by activating the immune system, in particular the chemokines and cytokines, and thus from microbiological attacks from the outside.

The stimulation of an endogenous antimicrobial protective system may be called an ideal mode of action, which does not have the disadvantages described above; because the activation of the antimicrobial principle of action takes place via the body's own metabolic control circuits of humans.

In investigating the mechanism of action of purines or purine alkaloids by gene expression studies (gene array) to stabilize hair growth, it was surprisingly found by the inventor that purines and purine alkaloids in hair roots showed significantly increased expression of the antimicrobial peptide dermcidin (DCD) gene, this being an indication that this will initiate its protein synthesis. The upregulation of the DCD gene was after a 120 hr. Incubation with, for example Purinalkaloide in human male hair roots a maximum of 14.5-fold compared to a control group, wherein after 24 hr. Incubation, the expression of the DCD gene in male hair follicles a maximum of 171-fold and Female was a maximum of 286-fold. By means of quantitative real-time PCR as confirmatory examination of the genes identified in the gene array, it was possible for 9 out of 12 different individuals (both sexes) strong upregulation of the DCD gene after purine or purine alkaloid treatment can be confirmed.

High gene induction represents the first step in a metabolic cascade that eventually leads to increased synthesis of the encoded peptide dermcidin in epithelial cells. The intrinsic stimulation is neither linked to the typical disadvantages of lack of compatibility nor to insufficient bioavailability, since the trigger purine or purine alkaloid for the release of dercidin has a particularly pronounced bioavailability. The intrinsic stimulation of dermcine synthesis via gene activation maintains the regulatory processes that prevent overdosage and thus undesired reactions. In particular, immune reactions to exogenous peptides are avoided, which can occur in topical, inhalative or oral dermidine or AMP application.

Furthermore, it is advantageous that the use of the means for stimulating the synthesis of the anionic DCD-1L leads.

It is known that DCD-1L kill pathogenic microorganisms such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Rifampin and Isoniazid-resistant Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cytogen genes, Salmonella thyphimurium, and Candida albicans can.

Therefore, it is further envisaged that the use of the agent can be enteral, intragastric, inhalative, intranasal, vaginal, (per) cutaneous or topical.

It is also part of the invention that the agent is a cosmetic agent.

It is provided that in the form of a hair treatment agent, in particular rinses, cures, care creams, cleansers, hair tonics, scalp solutions, shampoos, fortifiers, gels, foams or in the form of a skin treatment agent, especially skin creams, masks, packs, wash emulsions, wash gels, aqueous alcoholic tonic solutions, serums, skin gels, lotions, fluids, deodorants or Antiperspirant or in the form of a treatment agent for the oral cavity, especially mouthwashes and ointments.

It is further conceivable that the agent is a pharmaceutical agent. However, it is also conceivable that the agent is added to a pharmaceutical product or drug.

A further embodiment of the invention provides that the agent contains caffeine.

A development of the invention provides that the agent biocidal active substances selected from the group consisting of zinc compounds, in particular zinc pyrithione, zinc ricinoleates, zinc PCA or inorganic zinc salts, organohalogen compounds, in particular 2,4,4'-trichloro 2'-hydroxydiphenyl ether (Irgasan), l, 6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, polyalcohols, especially clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7 1 l-trimethyl-2,6,10-dodecatrien-1-ol).

Furthermore, it is advantageous that the agent contains anti-inflammatory agents, in particular selected from the group consisting of bisabolol, panthenol and tocopherol.

It is also envisaged that the agent contains plant extracts, in particular selected from the group consisting of Echinacea, Ferula, Calendula and Melaleuca.

It is also part of the invention that the purine and / or purine alkaloid is present as a derivative.

For the agent according to the invention it is provided that the purine and / or purine alkaloid in a concentration of 0.001 to 10,000 parts by weight, preferably in a concentration of 0.01 to 5.00 parts by weight, most preferably in a concentration of 0.1 to 2.0 wt. Purines and / or purine alkaloids may be formulated together with other active ingredients and / or solvents, surfactants, emollients, vegetable, animal or synthetic lipids, fats or oils.

To stabilize the consistency and the flow behavior, it is further provided that the agent according to the invention contains gel formers on an inorganic or organic basis.

Buffer systems with organic or inorganic acids keep the desired pH stable, preferably in the physiologically preferred range of 5-6.

Furthermore, it is advantageous that the agent contains active substances from the group of vitamins and vitamin derivatives, light protection filters, trace elements and / or plant extracts with biologically active phytoflavones, phytohormones and / or radical scavengers.

It is further envisaged for the agent according to the invention that antioxidants are used to stabilize purines and / or purine alkaloids and / or other active ingredients in the long term.

Preferred active compounds from the aforementioned fields are humectants, in particular selected from the water-soluble polyhydric low to medium-chain alkanols (C2 to C6) with multiple hydroxyl groups and / or the water-soluble polyether compounds, straight-chain or branched-chain of glycols or diols or triols or polyols 3-20 monomer units and mixtures thereof. Preferred monomers are 1,2-propylene glycol, 2-methyl-1,3-propanediol, glycerol, butylene glycols such as 1,2-butylene glycol, 1,3-butylene glycol and 1,4-butylene glycol, pentylene glycols, hexanediols such as 1,6-hexanediol Hexane triols such as 1,2,6-hexanetriol, 1,8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol, inositol or xylitol and mixtures of the aforementioned substances.

Suitable water-soluble polyethylene glycols are selected from PEG-n with n = 2 to 20 and mixtures thereof, where n = 3 to 8 are preferred. Sugar and certain sugar derivatives such as fructose, glucose, maltose, maltitol, mannitol, inositol, sucrose, trehalose, xylose, rhamnose and fucose can also be added to the composition according to the invention. The proposed sugar derivatives also include mono- or dicarboxylic acids of hexoses or pentoses. Likewise, amino acids, either individually or as a mixture, can be formulated as moisturizers. Other humectants are taurine, allantoin, (2-hydroxyethyl) urea, biosaccharides gum-1 and glycosaminoglycans and their salts and / or esters, especially hyaluronic acid, its salts and its silanol derivatives.

It is further contemplated that the agent of the invention cooperates with one or more humectants. The humectant here is in a concentration of 0.01 to 35.00 parts by weight, preferably 1.0 to 15.0 parts by weight, most preferably in a concentration of 5.0 to 10.0 parts by weight, based on the overall recipe, before.

Other preferred agents which the agent may contain are selected from oligomers and polymers of amino acids as well as natural betaine compounds.

Physiological active ingredients include vitamins, provitamins and vitamin precursors of groups A, B, C, E, H and K and their derivatives, alpha-hydroxycarboxylic acids, alpha-ketocarboxylic acids, beta-hydroxycarboxylic acids and their ester, lactone or salt form, flavonoids and flavonoid-rich plant extracts, isoflavonoids and isoflavonoid-rich plant extracts, polyphenols and polyphenol-rich plant extracts, ubiquinone and ubiquinol and their derivatives, ectoine, inorganic and organic UV filter substances, self-tanning active ingredients and skin-lightening active ingredients, and oligopeptides with alkyl or silanol side chains.

Furthermore, the invention provides that the agent comprises a mixture of a plurality of oligopeptides.

If it is necessary that the above-described acids must be neutralized or neutralized acids or salts are used, cations of ammonium, alkali metal, aluminum, calcium, copper, magnesium, manganese salts and zinc, preferably the Aluminum, potassium, magnesium, sodium, manganese and zinc salts are added to the agent. Furthermore, the invention provides that the agent poly- or oligopetides of N-acylamino acids having chain lengths of 2-26 carbon atoms.

These can be obtained both by synthesis of individual components and by hydrolysis of complex peptides. Starting peptides are derived either from animal sources, in particular elastin, collagen, keratin, silk and milk protein protein hydrolysates or from preferably plant sources, such as the plant family of legumes, grasses or cereals, the kernels of apricots or almonds.

It is part of the invention that the agent also contains formulations with surface-active properties.

Here, the use of protein hydrolysates and their acyl derivatives is provided, which may be present in the form of fatty acid condensation products or cationic protein hydrolysates, quaternary amino acids, oligopeptides, lipopeptides or acylated amino acids or peptides.

Exemplary of these are Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Silk, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl Silk Amino Acids, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl (substance names are taken from the European Inventory of Cosmetic Ingredients, (COSING)).

For hair and skin care products conditioning substances are particularly suitable as additives to the composition. For this purpose, for example, substances that bind to keratinic materials, i. The horny layer of the skin or the cuticle of the hair shaft attach and improve their physical and sensory properties used.

It is also envisaged that the agent may contain conditioning agents. This is beneficial because the conditioners smooth the surfaces of the skin and hair, repairing damaged areas and keeping them soft and supple.

For the invention, preferred conditioning agents are selected from fatty substances, especially vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, for example di-n-octyl ether and n-hexyl n-octyl ether, fatty acids, in particular linear and / or branched, saturated and / or unsaturated C8-30 Fatty acids, fatty alcohols, in particular saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms, ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or with 3-30, preferably 9-14 Propylene oxide units are propoxylated, ester oils, that is, esters of C6-30 fatty acids with C2-30 fatty alcohols, Hydroxycarbonsäurealkyle star, dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol diol or propylene glycol di (2-ethylhexanoate), symmetrical, asymmetrical or cyclic esters of carbonic acid with fatty alcohols such as glycerol carbonate or dicaprylyl carbonate, mono, di- and trifatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerol, which may be ethoxylated with an additional 1-10, preferably 7-9 ethylene oxide units, such as PEG-7 glyceryl cocoate, waxes, especially insect waxes, plant waxes, fruit waxes, ozokerite, microwaxes, ceresin , Paraffin waxes, triglycerides of saturated and optionally hydroxylated C16-30 fatty acids, such as, for example, hardened triglyceride fats, phospholipids, for example soya lecithin, egg lecithin and cephalins, silicone compounds selected from cyclopentasiloxane, cyclohexasiloxane and silicone polymers, with further ligands as needed may be crosslinked, such as alkylene, arylene or alkyl / arylene, polyethers of glycol, propylene glycol or glycerol.

Furthermore, the invention provides that the components added to the agent are quaternized.

The amount used for the Emolientien and / or care agents added to the agent in this case in a concentration of 0.1 to 50.0 wt.%, Preferably in a concentration from 0.1 to 20.0% by weight and most preferably in a concentration of 0.1-15.0% by weight, based in each case on the formulation.

Because of the variety of candidate drugs that may be added to the agent, the following list may be exemplary only and is intended to clarify substantially the potential chemical structures of the drugs of interest.

Some of the conditioning agents included in the composition of the invention may be unstable in the presence of oxygen. Therefore, the invention provides that they are stabilized with antioxidants.

Particularly suitable below are exemplified enumerated components:

Advantageously, the antioxidants are selected from the group consisting of the amino acids (eg, glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and their derivatives, DL-carnosine, D-carnosine, L Carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg alpha-carotene, beta-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols ( For example, thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, linoleyl and their Salts), dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (eg buthionine sulfoximines, homocysteinsulfoximine, buthionine sulfones, penta, hexa, heptathionine sulfuxi min) in very low tolerated dosages, also (metal) chelators (e.g. alpha-hydroxy fatty acids, phytic acid, glycosylrutin, ferulic acid, furfurylidene glucitol, butylhydroxytoluene, butylhydroxyanisole, nordihydroguajacic acid, nordihydroguajaretsäure, trihydroxybutyrophenone).

Cleaning products for the skin or hair are preferably composed of a combination of anionic surfactants, amphoteric, nonionic, more rarely cationic surfactants, for example fatty alcohols of chain length C10 to C16, which are esterified with inorganic acids such as phosphoric acid, sulfuric acid or acetic acid. To improve the skin compatibility These fatty acid esters are modified with polyethers. Suitable anionic surfactants are, for example, lauryl ether sulfate, lauryl sulfate, myristyl sulfate, laureth sulfosuccinates, ether carboxylates with a variable degree of ethoxylation, ether sulfonates based on amino acids, sugars and fatty alcohols.

It is envisaged that these with amphoteric cosurfactants such as cocamidopropyl betaine, cocoamphodiacetate, furthermore decyl polyglycosides, dodecyl polyglycosides, trilaureth 4-phosphates, di / mono sodium cocoamphoacetate, acyl / dialkylethylenediamine, for example, sodium acylampho acetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, Sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acyl amphopropionate, N-alkylamino acids such as aminopropylalkylglutamide, alkylamino-propionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.

In this case, the anionic surfactants are preferably used in salt form. Suitable cations are alkali metal and alkaline earth metal ions, in particular sodium, potassium and magnesium.

Nonionic surfactants are, for example, sarcosinates, e.g. Myristoyl sarcosinates, TEA lauroyl sarcosinates, Na lauroyl sarcosinates, Na cocoyl sarcosinates, fatty acid having a chain length of C10 to C20, saturated or unsaturated, acyl lysinates, alaninates or glycinates or fatty alcohol polyethers having 10 to 20 ethylene oxide or propylene oxide units.

Cationic surfactants are primarily the already described as conditioning components quaternized N compounds from the group of amino acids, amino sugars or peptides.

Furthermore, it is provided that gel formers are contained in the means for optimizing the flow behavior.

Gelling agents are, for example, organic thickeners, such as gum arabic, xanthan gum, sodium alginate, starch and starch derivatives (eg distarch phosphate), cellulose, cellulose derivatives, preferably methyl cellulose, Hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,

Hydroxypropylmethylcellulose or inorganic thickening agents, such as aluminum silicates, such as organically modified or unmodified hectorites, bentonites, or the like, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate. Furthermore, biopolymers such as chitin or chitin derivatives or poly-glucuronic or polygalacturonic acids and their amides are suitable. Another group of particularly effective gels consists of modified polymers of acrylic acid.

It is further contemplated that the thickener is contained in the gel in a concentration of 0.1 to 30.0 parts by weight, preferably in a concentration of 0.5 to 15.0 parts by weight.

Prescriptions for the skin and hair care mainly consist of oils and care substances, which have to be stabilized in aqueous systems by means of emulsifiers.

Therefore, the invention provides that the agent contains emulsifiers.

Suitable emulsifiers are, for example, PEG-n hydrogenated castor oil, PEG-n caprylic acid / capric acid glycerides, glyceryl oleate mixed with propylene glycol, PEG-n-stearate, ceteth-n, ceteth-n, polysorbate n, glyceryl stearate in admixture with PEG-n, glyceryl myristate, Glyceryl laurate, PEG-n-sorbitan peroleate, laureth-n, ceteareth-n, isostearyl glyceryl ether, cetylstearyl alcohol in admixture with sodium cetyl stearyl sulfate, lameth-n, steareth-n, glyceryl stearate in admixture with PEG-n stearate. PEG-n-stearate, glycol distearate, PEG-n-dodecyl glycol, polyglyceryl-n-PEG-n-stearate, ceteareth-n, methyl glucose sesquistearate, steareth-n, PEG-n-stearate, steareth-n in admixture with PEG-n Distearate, steareth-n, steareth-n, isosteareth-n, PEG-n dodecyglycol copolymer, methoxy-PEG-n dodecyl glycol copolymer, PEG-n sorbitan peroleate, PEG-n sorbitan perisostearate, PEG-n-glyceryl stearate, PEG- n-glyceryl stearate, PEG-n beeswax, polyglyceryl n-laurate, isostearyl diglyceryl succinate, stearamidopropyl PG-dimonium chloride phosphate, glyceryl stearate SE, PEG-n-methyl glucose sesquistearate, ceteareth-n, glyceryl stearate citrate, cetyl phosphate, sorbitan sesquioleate, trilaureth-n-phosphate, polyglyceryl glucose distearate , Potassium cetyl phosphate, isosteareth-n, polyglyceryl-n-sesquiisostearate, ceteth-n, oleth-n, Isoceteth-n, glyceryl stearate in admixture with ceteareth-n, ceteareth-n, cetylstearyl alcohol and cetyl palmitate, cetylstearyl alcohol in admixture with PEG-n-stearate, PEG-n-stearate, PEG-n-stearate, PEG-n-stearate, where n represents the number of ether compounds and can be 2 to 100.

So that the agent according to the invention can be best distributed on the surface of skin or hair, gastrointestinal or respiratory tract or vaginal area with the abovementioned active ingredient combinations, a specific galenic formulation is necessary. This depends on the individual needs of the user.

It is advantageous that the agent according to the invention for dermatological applications in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in-oil-in-water emulsion, macroemulsion, microemulsion, PIT emulsion, nanoemulsion, hydrodispersion, hydrogel, lipogel, mono- or multiphase solution, foam, aqueous-alcoholic solution or surfactant formulation is present.

For the respiratory tract, especially the nose, it is provided that the agent with applicators, such as dosing tips or spray dosing in the form of aqueous, aqueous-alcoholic solutions, lotions or gels is administered.

It is further provided for skin care products, so-called cures and packs, skin protection creams, sunscreen lotion, nutrient creams, day creams or night creams or ampoules, that these means of the invention is attached.

It is further provided for deodorant or antiperspirant products that the agent according to the invention is used for sprays, roll-ons and deodorants.

For skin or hair cleansers containing the agent according to the invention, for example, soaps, cleansing gels, cleansing gels, shampoos, foams, cleansing sprays, rinses, cures, alcoholic lotions, hair creams or scalp waters are provided. The following formulation examples are intended to illustrate the subject matter of the invention without limiting it thereto. All data are in parts by weight based on the total composition. The substance names are taken from the binding inventory of cosmetic ingredients, COSING.

Mild hair and body shampoo (by weight)

Xanthan Gum 1.00

Coco Glucoside 2.00

Sodium cocoyl alaninate 5.00

Sodium myristate 10.00

Glycerol 0.20

Adenine 0.30

Citric Acid 0.50

Caffeine 1.00

Potassium sorbate 0.20

Aqua ad 100

Anti-dandruff shampoo (in% by weight)

Sodium cocoyl alaninate 7.00

Sodium Laureth Sulfate 11.00

Cocamidopropyl Betaine 29.00

Glycerin 5.00

Theobromine 2.00

Zinc Pyrithione 0.80

Zinc PCA 2.00

Polysorbate 20 1.00

Perfume 0.20

Panthenol 0.50

Methylpropanediol, caprylyl glycol,

Phenylpropanol 3.00

Aqua ad 100 Deodorant cream (in percent by weight)

Isohexadecane 5.00

Ethylhexyl Stearate 8.00

Decyl Oleate 6,00

Phenoxyethanol 0.60

Ethylhexylglycerol 0.40

Sorbitan Oleate 3.00

Polyglyceryl-3 Polyricinoleate 2.00

Sucrose polystearate 1.00

Theophylline 0.10

Tocopheryl acetate 1.00

Magnesium Sulfate 0,70

Glycerin 5.00

Perfume 0.30

Octyldodecanol 2.00

Aqua ad 100

Face cream (in percent by weight)

Pectin 0.50

Glycerol 3.00

Carbomer 0.20

Glyceryl Stearate Citrate 3.00

Sucrose stearate 1.00

Cetearyl Alcohol 1.50

Ethylhexyl palmitate 9.00

Isoamyl Laurate 6.00

Helianthuus Annuus Seed Oil

Unsaponifiables 2.00

Tocopherol, 0.20

Caffeine 0.30

Helianthus Annuus Seed Oil 2.00

Theobromine 0.20

Phenoxyethanol 0.80

Ethylhexylglycerol 1.00

Arginine 0.30

Perfume 0.20

Xanthan gum 0.25

Sodium hydroxides 0.10

Aqua ad 100 Foot gel (in percent by weight)

Aqua ad 100

Glycerol 4.00

Phenoxyethanol, 0.50

Ethylhexylglycerol 2 0.50

Carbomer 0.15

Farnesol 0.50

1-methylxanthines 0.20

Zinc PCA 0.30

Acrylates / C10-30 alkyl acrylates

Crosspolymer 0.25

Sodium hydroxides 0.10

Alcohol 3.00

Theophylline 2.00

Scalp tonic (in percent by weight

Aqua ad 100

Glycerol 0.20

Alcohol 40,00

Panthenol 0.30

Carbomer 0.15

Farnesol 0.10

Xanthines 0.20

Biotin 0.01

Acrylates / C10-30 alkyl acrylates

Crosspolymer 0.10

Sodium hydroxides 0.01

Magnesium gluconate 0.20

Mouthwash (in% by weight)

Aqua ad 100

Glycerin 10.00

Alcohol 10.00

Sodium Phosphates 1.00

Xylitol 0.15

1-methylxanthines 0.10

Aroma 0.20

Menthol 0.01

CI 42090 0,01

Potassium Sorbate 0.10

Sodium Benzoate 0.05

Claims

Use of an agent for stimulating the expression of antimicrobial peptides (AMP), wherein the agent is a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-l-methylxanthine (IBMX) and Contains 1-methylxanthine.

2. Use of an agent according to claim 1,

characterized in that the antimicrobial peptide (AMP) is dercidin (DCD).

3. Use of an agent according to claim 2,

characterized in that the dercidin is the anionic DCD-1L.

4. Use of a composition according to claim 1,

characterized in that the agent is enteral, intragastric, inhalative, intranasal, vaginal, cutaneous or topically applicable.

5. Use of an agent according to claim 1,

characterized in that the agent is a cosmetic agent.

6. Use of a composition according to claim 5,

characterized in that the cosmetic agent is in the form of a hair treatment agent, in particular rinses, cures, care creams, cleansers, hair tonics, scalp solutions, shampoos, fixatives, gels, foams or in the form of a skin treatment agent, in particular skin creams, masks, packs, wash emulsions, wash gels, aqueous alcoholic, tonic solutions, serums, skin gels, lotions, fluids, deodorant or antiperspirant products or in the form of a treatment agent for the oral cavity, in particular mouthwashes and ointments.

7. Use of an agent according to claim 1,

characterized in that the agent is a pharmaceutical agent.

8. Use of an agent according to claim 1,

characterized in that the agent contains caffeine.

9. Use of an agent according to claim 1,

characterized in that the agent biocidal agents selected from the group consisting of zinc compounds, in particular zinc pyrithione, zinc ricinoleates, zinc PCA or inorganic zinc salts, organohalogen compounds, in particular 2,4,4'-trichloro-2'-hydroxydiphenyl ether ( Irgasan), 1,6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4 '-' trichlorocarbanilide, polyalcohols, especially clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7,1 l- Trimethyl-2,6,10-dodecatrien-1-ol).

10. Use of an agent according to claim 1,

characterized in that the agent contains anti-inflammatory agents, in particular selected from the group consisting of bisabolol, panthenol and tocopherol.

11. Use of a composition according to claim 1,

characterized in that the agent contains plant extracts, in particular selected from the group consisting of Echinacea, Ferula, Calendula and Melaleuca.

12. Use of an agent according to claim 1,

characterized in that the purine and / or Purinalkaloid is present as a derivative.

13. Use of an agent according to claim 1,

characterized in that the purine and / or purine alkaloid in a concentration of 0.001 to 10 parts by weight, preferably in a concentration of 0.01 to 5.0 parts by weight, most preferably in a concentration of 0.1 to 2.0 Gew.- present.